Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 10/20 | 0.58 |
| ▸ | CA2 | P00918 | 10/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101846 | 1.00 | KMT2A (0.63) | KMT2AUSP2CA1CA2CA12 | |
| SCHEMBL6155655 | 0.90 | KMT2A (0.77) | KMT2ACA1CA2CA12CA9 | |
| SCHEMBL9851212 | 0.87 | KMT2A (0.63) | KMT2AUSP2CA1CA2ALDH1A1 | |
| SCHEMBL10014710 | 0.86 | USP2 (0.76) | KMT2AUSP2ALDH1A1CYP3A4TSHR | |
| SCHEMBL9967356 | 0.86 | KMT2A (0.85) | KMT2AUSP2CA1CA2ALDH1A1 | |
| SCHEMBL20589125 | 0.86 | KMT2A (0.85) | KMT2AUSP2CA1CA2ALDH1A1 | |
| SCHEMBL20968094 | 0.86 | KMT2A (0.61) | KMT2AUSP2CA1CA2ALDH1A1 | |
| SCHEMBL3194211 | 0.84 | MEN1 (0.53) | KMT2AUSP2ALDH1A1CYP3A4TSHR | |
| SCHEMBL13998010 | 0.84 | MEN1 (0.53) | KMT2AUSP2ALDH1A1CYP3A4TSHR | |
| SCHEMBL3190391 | 0.82 | MEN1 (0.68) | KMT2ALMNANPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | claimed |
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | claimed |
| US-20150332806-A1 | CURABLE RESIN COMPOSITION, INSULATING FILM, PREPREG, CURED PRODUCT, COMPOSITE, AND SUBSTRATE FOR ELECTRONIC MATERIAL | ZEON CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7507784-B2 | Liquid crystalline thermosets from ester, ester-imide, and ester-amide oligomers | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507784-B2 | Liquid crystalline thermosets from ester, ester-imide, and ester-amide oligomers | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 2009-03-24 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
| US-5026871-A | Cylic phenolic resins; prepregs; intermediates for polyimides; high strength | CIBA-GEIGY CORPORATION (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0425438-A2 | Novel oligomers | CIBA-GEIGY AG (CH) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | KMT2A 1756/4885USP2 1946/4885CA1 3308/4885 |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | KMT2A 1756/4885USP2 1946/4885CA1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.